Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.The proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences' expertise in immune-mediated indications with Biogen's global development and commercial experience in rare diseases.Biogen plans to leverage its existing global development and commercialization capabilities in rare disease and its strong scientific expertise in immunology to support the advancement of felzartamab and the HI-Bio pipeline.The total potential deal value can go up to $1.8 billion, should the felzartamab programs achieve certain development milestones.In addition to lead program felzartamab, the HI-Bio pipeline includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial..

Biogen Inc.（BIIB）和私营生物技术公司人类免疫生物科学（Human Immunology Biosciences）周三宣布，两家公司已达成最终协议，根据该协议，Biogen已同意以11.5亿美元的预付款和高达6.5亿美元的潜在里程碑付款收购HI-Bio。拟议的收购建立在Biogen免疫学能力的基础上，计划将人类免疫学生物科学在免疫介导适应症方面的专业知识与Biogen在罕见疾病方面的全球发展和商业经验相结合。Biogen计划利用其在罕见疾病方面的现有全球开发和商业化能力以及在免疫学方面的强大科学专业知识，支持felzartamab和HI-Bio管道的发展。如果felzartamab项目达到某些发展里程碑，则潜在交易总价值可能高达18亿美元。除了领先的felzartamab项目外，HI-Bio管道还包括izastobart/HIB210，这是一种目前正在进行1期试验的抗C5aR1抗体。。

Biogen seeks to retain expertise and talent from HI-Bio and establish a San Francisco Bay Area team focused on expanding our efforts in immune-mediated diseases.Biogen expects to finance the acquisition with cash and may also draw on its revolving credit agreement. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals and is currently anticipated to close in the third quarter of 2024.The acquisition of HI-Bio is not expected to impact Biogen's previously issued 2024 guidance.

Biogen寻求保留HI Bio的专业知识和人才，并建立一个旧金山湾区团队，专注于扩大我们在免疫介导疾病方面的努力。Biogen预计将用现金为收购提供资金，并可能利用其循环信贷协议。该交易受惯例成交条件的约束，包括收到必要的监管批准，目前预计将于2024年第三季度完成。收购HI Bio预计不会影响Biogen之前发布的2024年指南。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股